XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Unaudited Interim Statements of Financial Position - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
ASSETS    
Fixed maturities available for sale, at fair value (amortized cost: 2020 - $1,599,264; 2019–$1,437,796) $ 1,808,546 $ 1,550,096
Fixed maturities, trading, at fair value (amortized cost: 2020 - $17,718; 2019–$14,221) 17,857 13,700
Equity securities, at fair value (cost: 2020 - $5,065; 2019–$5,139) 8,438 7,512
Policy loans 212,519 211,986
Commercial mortgage and other loans (net of $448 and $165 allowance for credit losses at September 30, 2020 and December 31, 2019, respectively) 136,705 [1] 143,098
Other invested assets (includes $29,122 and $24,726 of assets measured at fair value at September 30, 2020 and December 31, 2019, respectively) 103,429 89,536
Total investments 2,287,494 2,015,928
Cash and cash equivalents 68,360 55,924
Deferred policy acquisition costs 213,072 178,813
Accrued investment income 21,027 19,539
Reinsurance recoverables 4,116,435 3,200,642
Receivables from parent and affiliates 32,775 32,820
Income taxes receivable 0 6,268
Other assets 20,042 21,203
Separate account assets 15,887,732 15,904,208
TOTAL ASSETS 22,646,937 21,435,345
LIABILITIES    
Future policy benefits 3,235,868 2,302,959
Policyholders’ account balances 2,508,775 2,424,120
Cash collateral for loaned securities 2,731 2,481
Income taxes payable 2,528 [1] 0
Short-term debt to affiliates 0 89
Payables to parent and affiliates 13,661 24,958
Other liabilities 163,252 [1] 140,628
Separate account liabilities 15,887,732 15,904,208
Total liabilities 21,814,547 20,799,443
EQUITY    
Common stock ($5 par value; 400,000 shares authorized, issued and outstanding) 2,000 2,000
Additional paid-in capital 348,735 268,021
Retained earnings 323,986 280,246
Accumulated other comprehensive income (loss) 157,669 85,635
Total equity 832,390 635,902
TOTAL LIABILITIES AND EQUITY $ 22,646,937 $ 21,435,345
[1] September 30, 2020 amounts include the impacts of the January 1, 2020 adoption of ASU 2016-13. See Note 2 for details.